AR109775A1 - METHOD FOR PRODUCING A PHARMACEUTICALLY STABLE COMPOSITION PRESENTED AS A WATER SOLUTION - Google Patents

METHOD FOR PRODUCING A PHARMACEUTICALLY STABLE COMPOSITION PRESENTED AS A WATER SOLUTION

Info

Publication number
AR109775A1
AR109775A1 ARP170102733A ARP170102733A AR109775A1 AR 109775 A1 AR109775 A1 AR 109775A1 AR P170102733 A ARP170102733 A AR P170102733A AR P170102733 A ARP170102733 A AR P170102733A AR 109775 A1 AR109775 A1 AR 109775A1
Authority
AR
Argentina
Prior art keywords
producing
composition presented
aqueous solution
pharmaceutical composition
stabilized pharmaceutical
Prior art date
Application number
ARP170102733A
Other languages
Spanish (es)
Original Assignee
Obschestvo S Ogranichennoi Otvetstvennostyu “Nauchnotehnologicheskaya Farm Firma “Polysan”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obschestvo S Ogranichennoi Otvetstvennostyu “Nauchnotehnologicheskaya Farm Firma “Polysan” filed Critical Obschestvo S Ogranichennoi Otvetstvennostyu “Nauchnotehnologicheskaya Farm Firma “Polysan”
Publication of AR109775A1 publication Critical patent/AR109775A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se relaciona con la industria química y farmacéutica y, en particular, con un método para producir una composición farmacéutica estabilizada presentada como una solución acuosa que se puede usar para obtener un fármaco intravenoso que contiene ácido succínico, nicotinamida, inosina y riboflavina-mononucleótido como los ingredientes activos y que posee propiedades citoprotectoras. Un método para producir la composición farmacéutica conocida estabilizada presentada como una solución acuosa que permitiría mejorar su seguridad en el uso a través de la aplicación de esterilización térmica. Un método para producir una composición farmacéutica estabilizada presentada como una solución acuosa que contiene ácido succínico, inosina, nicotinamida, riboflavina-mononucleótido de sodio como ingredientes activos, mediante la disolución de estos en agua con la subsiguiente filtración estéril, donde, la composición se suplementa con uno o varios de los componentes farmacéuticamente aceptables como el agente estabilizador que se ha de seleccionar del grupo que incluye hidróxido de sodio, tris(hidroximetil)aminometano (TRIS), etanolamina, dietanolamina, carbonato de sodio, meglumina, hasta una solución estable con pH entre 6,0 y 8,0; siendo la proporción de componentes, % en peso, como sigue: @@@@@@@@@It relates to the chemical and pharmaceutical industry and, in particular, to a method for producing a stabilized pharmaceutical composition presented as an aqueous solution that can be used to obtain an intravenous drug containing succinic acid, nicotinamide, inosine and riboflavin-mononucleotide such as active ingredients and that has cytoprotective properties. A method for producing the known stabilized pharmaceutical composition presented as an aqueous solution that would improve its safety in use through the application of thermal sterilization. A method for producing a stabilized pharmaceutical composition presented as an aqueous solution containing succinic acid, inosine, nicotinamide, riboflavin-sodium mononucleotide as active ingredients, by dissolving these in water with subsequent sterile filtration, where the composition is supplemented with one or more of the pharmaceutically acceptable components as the stabilizing agent to be selected from the group that includes sodium hydroxide, tris (hydroxymethyl) aminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate, meglumine, to a stable solution with pH between 6.0 and 8.0; being the proportion of components,% by weight, as follows: @@@@@@@@@@

ARP170102733A 2016-09-29 2017-09-29 METHOD FOR PRODUCING A PHARMACEUTICALLY STABLE COMPOSITION PRESENTED AS A WATER SOLUTION AR109775A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2016138632A RU2629204C1 (en) 2016-09-29 2016-09-29 Method for obtaining of stabilized pharmaceutical composition as aqueous solution

Publications (1)

Publication Number Publication Date
AR109775A1 true AR109775A1 (en) 2019-01-23

Family

ID=59744837

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102733A AR109775A1 (en) 2016-09-29 2017-09-29 METHOD FOR PRODUCING A PHARMACEUTICALLY STABLE COMPOSITION PRESENTED AS A WATER SOLUTION

Country Status (14)

Country Link
CN (1) CN110022858B (en)
AR (1) AR109775A1 (en)
BR (1) BR112019006167A2 (en)
CL (1) CL2019000810A1 (en)
CO (1) CO2019004133A2 (en)
EA (1) EA029693B1 (en)
EC (1) ECSP19030392A (en)
MD (1) MD4774C1 (en)
MY (1) MY193623A (en)
PH (1) PH12019500702A1 (en)
RU (1) RU2629204C1 (en)
UA (1) UA118387C2 (en)
UY (1) UY37426A (en)
WO (1) WO2018063028A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2651047C1 (en) * 2017-05-04 2018-04-18 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Drug composition of cytoprotective action and method for production thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2059417C1 (en) * 1992-10-01 1996-05-10 Данилевич Василий Николаевич Method for sterilization of nutrient media
KR20010033563A (en) * 1997-12-25 2001-04-25 다카하시 데츠로 Water-base liquid preparation
EA001099B1 (en) * 1999-06-10 2000-10-30 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Injecting medical preparation "citoflavin" possessing cito-pretecting effect
JP2002161047A (en) * 2000-11-28 2002-06-04 Terumo Corp Hemoglobin solution and hemoglobin-containing liposome
RU2238108C1 (en) * 2003-01-27 2004-10-20 Нестерук Владимир Викторович Method for sterilizing sodium chloride injection solution
CN1679615A (en) * 2005-02-04 2005-10-12 北京阜康仁生物制药科技有限公司 Compound infantile energy mistura soluble vitamin preparation and use thereof
CN101601647B (en) * 2009-07-09 2010-09-15 周晓东 Riboflavine sodium phosphate composition injection and preparation method thereof
RU2536994C1 (en) * 2013-05-17 2014-12-27 Общество С Ограниченной Ответственностью "Нпо "Нефрон" Concentrated acidic component, kit for producing it, concentrated solution of acidic component for producing hemodialysis solution and method for producing it
WO2015113035A1 (en) * 2014-01-27 2015-07-30 Abbott Laboratories Aseptic filtration process
US20170224726A1 (en) * 2014-02-18 2017-08-10 Glenn Abrahmsohn Compositions and methods for pain relief without numbness
US10627407B2 (en) * 2015-03-12 2020-04-21 Mars, Incorporated Ultra high resolution mass spectrometry and methods of using the same

Also Published As

Publication number Publication date
WO2018063028A1 (en) 2018-04-05
MY193623A (en) 2022-10-20
MD4774B1 (en) 2021-11-30
EA201700072A1 (en) 2018-03-30
BR112019006167A2 (en) 2019-06-18
RU2629204C1 (en) 2017-08-25
ECSP19030392A (en) 2019-08-30
CL2019000810A1 (en) 2019-08-02
CO2019004133A2 (en) 2019-09-30
UA118387C2 (en) 2019-01-10
UY37426A (en) 2018-04-30
CN110022858B (en) 2021-12-14
MD20190038A2 (en) 2019-10-31
CN110022858A (en) 2019-07-16
MD4774C1 (en) 2022-06-30
PH12019500702A1 (en) 2019-11-25
EA029693B1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
PE20190709A1 (en) DERIVED FROM PIRAZOLOPIRIDINA THAT HAS THE AGONIST EFFECT OF THE GLP-1 RECEPTOR
CL2017002155A1 (en) Substituted nucleoside derivatives useful as antineoplastic agents
CL2018003504A1 (en) Substituted carbonucleoside derivatives useful as antineoplastic agents.
AR088381A1 (en) FORMULATIONS OF ETANERCEPT STABILIZED WITH MEGLUMINA
MY189761A (en) Quinazoline derivatives used to treat hiv
CL2019001565A1 (en) Pharmaceutical composition for preventing or treating cancer, comprising the crystalline polymorph of tetraarsenic hexoxide.
AR065806A1 (en) DERIVATIVES OF QUINOLINA, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF Rheumatoid ARTHRITIS.
CO2019005729A2 (en) Preparation of solid cyclodextrin complexes for the supply of ophthalmic active pharmaceutical ingredients
PE20130063A1 (en) ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
CU20200008A7 (en) SUBSTITUTE DIHYDROOXADIAZINONE COMPOUNDS USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES, METHODS FOR PREPARING SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR036248A1 (en) DERIVATIVES OF 2H-PIRIDAZIN-3-ONA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND A PROCESS FOR THE PREPARATION OF SUCH DERIVATIVES AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
AR098775A1 (en) COMPOSITIONS FOR ORAL CARE CONTAINING CALCIUM CARBONATE AND SILICA
BR112018073524A2 (en) compound, pharmaceutical composition, combination, use of a compound or a pharmaceutically acceptable salt thereof, and method of treating a disease or condition.
DOP2016000007A (en) SUBSTITUTED PIRAZOLPIRIDINS
DOP2016000268A (en) AMIDO-AZOLE COMPOUNDS SUBSTITUTED AS TNKS1 AND/OR TNKS2 INHIBITORS
CL2020003015A1 (en) Preparative-scale conversion of goniautoxins into neosaxitoxin
AR098774A1 (en) COMPOSITIONS FOR ORAL CARE THAT INCLUDE CARBONATE OF CALCIUM AND TALCO
CO2020006257A2 (en) Injectable pharmaceutical compositions of isoxazoline and uses thereof against parasitic infestation
PE20171246A1 (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE HIGH PURITY CANGRELOR AND METHODS FOR THE PREPARATION AND USE OF SAME
ECSP19030392A (en) METHOD TO PRODUCE A PHARMACEUTICALLY STABLE COMPOSITION PRESENTED AS AN AQUEOUS SOLUTION
AR087371A1 (en) FORMULATIONS OF (TRIMETOXIFENILAMINO) PYRIMIDINYL, METHODS
AR099202A1 (en) WATERY COMPOSITION CONTAINING AN OLIGODYNAMIC METAL
CL2013003137A1 (en) Oral liquid pharmaceutical composition containing divalproex sodium (2-15% w / v of the composition), and one or more excipients, whose ph is greater than 6; method of preparing the composition comprising: (a) mixing sodium hydroxide in purified water, (b) adding sodium divalproex and excipients; and (c) adjust ph over 6.
BR112018069144A2 (en) pharmaceutical or veterinary composition
AR122166A1 (en) DISHWASHER TABLET